Print

HVTN 502/Merck 023 (Step Study)

The purpose of the Merck/HVTN proof-of-concept trial is to obtain more information about the safety of the MRKAd5 HIV-1 gag/pol/nef, or trivalent, vaccine in humans and to learn if it can prevent HIV infection.

Trial Details:

IIb Terminated
Merck, HIV Vaccine Trials Network (HVTN) January 07, 2005
MRKAd5 HIV-1 gag/pol/nef Ad5 vectored with gag gene from the HIV-1 strain CAM-1, the pol gene from HIV-1 strain IIIB and the nef gene from HIV-1 strain JR-FL
MRKAd5 HIV-1 gag/pol/nef Viral Vector - Adeno
Australia, Canada, Dominican Republic, Haiti, Peru, Puerto Rico, USA 3,000
NCT00095576
https://clinicaltrials.gov/ct2/show/NCT00095576